![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Alto Neuroscience is a clinical-stage biopharmaceutical company with a mission to redefine neuropsychiatric care by leveraging neurobiology to develop personalized and highly effective treatment options. Through our AI-enabled biomarker platform, we combine rich sources of information on patients¿ b... Alto Neuroscience is a clinical-stage biopharmaceutical company with a mission to redefine neuropsychiatric care by leveraging neurobiology to develop personalized and highly effective treatment options. Through our AI-enabled biomarker platform, we combine rich sources of information on patients¿ brain activity and behavior to better identify which patients are more likely to respond to our novel product candidates. Show more
– ALTO-101 has been shown to positively impact cognition and key cognition-related EEG markers in humans when delivered orally – – Novel transdermal formulation of ALTO-101 exhibited favorable...
– Dr. Etkin recognized as a Bay Area winner out of 26 finalists by an independent panel of judges – – Entrepreneur Of The Year celebrates ambitious entrepreneurs who are shaping the future across...
Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO) today announced that Company management will participate in the Jefferies Global Healthcare Conference, taking place June 5-6, 2024, in New York...
– Mr. Hanley brings over two decades of leadership experience in product development and commercialization across a wide range of neuropsychiatric indications, including major depressive disorder...
– Initiated Phase 2 study of ALTO-203 in patients with MDD and anhedonia – – Reported positive Phase 1 data with transdermal formulation of novel PDE4 inhibitor, ALTO-101; achieved significantly...
Period † | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -1.34 | -11.8584070796 | 11.3 | 11.62 | 9.4 | 133930 | 10.50817538 | CS |
4 | -2.75 | -21.6365066876 | 12.71 | 12.78 | 9.4 | 103618 | 11.20442683 | CS |
12 | -4.08 | -29.0598290598 | 14.04 | 16.535 | 9.4 | 98392 | 12.80488716 | CS |
26 | -12.04 | -54.7272727273 | 22 | 24 | 9.4 | 184946 | 15.19363147 | CS |
52 | -12.04 | -54.7272727273 | 22 | 24 | 9.4 | 184946 | 15.19363147 | CS |
156 | -12.04 | -54.7272727273 | 22 | 24 | 9.4 | 184946 | 15.19363147 | CS |
260 | -12.04 | -54.7272727273 | 22 | 24 | 9.4 | 184946 | 15.19363147 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions